Clinical trials
Renal Cancer clinical trials
Below are recruiting renal cancer clinical trials, each written for real people, not researchers. We’re tracking 252 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07321197Recruiting
Kidney removal with or without lymph node removal for high risk kidney cancer
This study is for people with high-risk kidney cancer who are having their whole kidney removed. It compares surgery alone versus surgery plus removing lymph nodes from the tumor area to see if removing the nodes helps control the cancer better.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT05770037RecruitingPhase 2/Phase 3
Alectinib for ALK-positive cancers in teens and adults
This study tests whether alectinib can treat ALK-positive cancers in adults, teenagers, and children. It focuses on people whose cancer testing shows an ALK change, and who can start oral treatment and have a new tissue sample.
BelfastAges Any age - NCT04724018RecruitingPhase 1/Phase 2
Enfortumab and sacituzumab for metastatic bladder cancer
This Phase 1/2 trial tests whether combining sacituzumab govitecan with enfortumab vedotin (and in one group, pembrolizumab) can shrink or control metastatic urothelial (bladder/urinary tract) cancer. It’s mainly for people whose cancer has grown despite prior treatment.
Boston, MassachusettsAges 18 years+ - NCT03972657RecruitingPhase 1/Phase 2
Testing a new prostate and kidney cancer drug with immunotherapy
This early trial tests whether REGN5678 (nezastomig) is safe and how well it works, either by itself or with an immunotherapy drug (cemiplimab). It targets adults with metastatic castration-resistant prostate cancer and certain metastatic kidney cancers that have already been treated.
Gilbert, ArizonaAges 18 years+ - NCT07181720RecruitingPhase 1
CD70-targeted CAR-T therapy for advanced solid tumors
This trial tests a new treatment called CAR-T that targets a protein called CD70 on cancer cells. It is for people with advanced solid tumors that have not responded to or cannot tolerate standard treatments.
Hefei, AnhuiAges 18 years+ - NCT07115043RecruitingPhase 1/Phase 2
Study of AZD6750 for advanced solid tumors
This trial tests a new drug called AZD6750 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective.
Grand Rapids, MichiganAges 18 years+ - NCT06783348RecruitingPhase 2
Radioactive treatment for advanced kidney cancer
This trial tests a radioactive treatment (called radiopharmaceutical) that targets a protein called PSMA on kidney cancer cells. It is for people with advanced clear cell kidney cancer that has already been treated with immunotherapy and targeted therapy.
CaenAges 18–100 - NCT06720532Recruiting
Kidney function in men with prostate cancer getting a new targeted radiation therapy
This study looks at how a targeted radiation therapy called 177Lu-PSMA affects kidney function in men with a type of advanced prostate cancer. It aims to understand risk factors to help guide safe treatment.
MunichAges 18 years+ - NCT03804320Recruiting
Watching small kidney tumors over time instead of treating
This study follows people with small, solid kidney tumors using active surveillance (regular monitoring) rather than immediate surgery or treatment. It may help you understand whether careful watching is a safe option for certain early kidney tumors.
MilanAges 50 years+ - NCT06101290Recruiting
Local therapy for progressing spots in genitourinary cancers
This trial explores whether treating only the new or growing spots of cancer (called oligoprogression) with local therapies like radiation or ablation can help you stay on your current systemic treatment longer. It is for people with prostate, bladder, or kidney cancer that has started to progress in a few places.
Sacramento, CaliforniaAges 18 years+ - NCT07292168RecruitingPhase 1/Phase 2
Study of a new antibody for advanced tumors with FGFR1 protein
This trial tests an experimental antibody, OM-RCA-01, in people with advanced solid tumors that have high levels of a protein called FGFR1. It aims to see if the drug is safe and effective for those who have already tried other treatments.
Kazan'Ages 18 years+ - NCT06940518RecruitingPhase 2
Ivonescimab for advanced clear cell kidney cancer
This trial tests a new drug, ivonescimab, for people with advanced clear cell kidney cancer that has grown after at least one prior treatment. It may help shrink tumors or slow the cancer's growth.
Houston, TexasAges 18 years+ - NCT07297667RecruitingPhase 1
CAR T-cell therapy for GPNMB-positive solid tumours
This trial tests a new immune cell therapy (CAR T-cells) that targets a protein called GPNMB found on some tumour types. It's for people with advanced alveolar soft part sarcoma, certain kidney cancers, or triple-negative breast cancer that hasn't responded to standard treatments.
Calgary, AlbertaAges 15 years+ - NCT05086692RecruitingPhase 1/Phase 2
Beta-only IL-2 therapy for advanced solid tumors
This Phase 1/2 study tests a beta-only version of IL-2, an immune-stimulating treatment, to shrink or control advanced or metastatic solid tumors. It’s mainly designed to check safety and to see if it can help patients by improving tumor response.
San Diego, CaliforniaAges 18 years+ - NCT06053658RecruitingPhase 2
Tivozanib and Nivolumab for advanced kidney cancer
This trial tests a combination of two drugs (tivozanib and nivolumab) for people with advanced kidney cancer that is not clear cell type. It aims to see if this drug pair can shrink or slow the cancer.
Irvine, CaliforniaAges 18 years+ - NCT06479811RecruitingPhase 1
Radioactive drug for advanced neuroendocrine and other cancers
This trial tests a new radioactive drug, [212Pb]VMT-Alpha-NET, that targets a protein on certain cancer cells. It is for people with specific types of advanced cancers that have gotten worse and are not responding to standard treatments.
Bethesda, MarylandAges 18–120 - NCT05665361RecruitingPhase 1/Phase 2
Testing palbociclib plus sasanlimab for advanced kidney cancers
This study tests a combination of two medicines—palbociclib and sasanlimab—in people with advanced clear cell or papillary kidney cancer. It’s mainly designed to check safety (and early signs of how well the treatment may work) in these cancer types.
Bethesda, MarylandAges 18–100 - NCT06420167RecruitingPhase 2
Dapagliflozin for kidney AL amyloidosis
This trial tests whether a diabetes medicine called dapagliflozin can help protect kidney function in people with AL amyloidosis. You must live in Michigan and have stable or improving protein in your urine.
Detroit, MichiganAges 18 years+ - NCT05059444Recruiting
Blood test study to watch for cancer coming back
This study looks at whether blood tests can detect signs that cancer may return after curative-intent treatment. You would have blood drawn around your usual follow-up visits for up to 5 years, and your de-identified health data would be shared with study investigators.
Birmingham, AlabamaAges 18 years+ - NCT06040762Recruiting
Get moving before bladder cancer surgery
This study tests whether a home-based exercise program before surgery can help improve physical function in people with bladder or upper tract urothelial cancer. If you are planning to have surgery to remove your bladder or upper urinary tract, you may be able to join.
Seattle, WashingtonAges 18 years+ - NCT07223424RecruitingPhase 2
Patient preference study: shot vs infusion for immunotherapy
This study compares two ways to take immunotherapy drugs (nivolumab or pembrolizumab): as a shot under the skin (subcutaneous) versus an infusion into a vein (intravenous). It looks at which method patients prefer and is for people with certain advanced cancers where these drugs are already approved.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT07187778RecruitingPhase 2
Comparing two drugs before kidney cancer surgery
This trial tests two different medicines (belzutifan and pembrolizumab), given alone or together, before surgery to remove kidney cancer. The goal is to see if these treatments shrink the tumor and improve outcomes for people with high-risk kidney cancer.
Houston, TexasAges 18 years+ - NCT07187869RecruitingPhase 1
Cabozantinib plus nivolumab for kidney cancer with bone spread
This study tests whether adding a drug called cabozantinib to standard nivolumab treatment helps fight kidney cancer that has spread to bone. It aims to understand how the bone environment changes during treatment.
Houston, TexasAges 18 years+ - NCT07227402RecruitingPhase 3
Study of belzutifan and zanzalintinib for recurrent kidney cancer
This trial tests two new drugs, belzutifan and zanzalintinib, for people with advanced kidney cancer that returned after or within 2 years of finishing an immunotherapy treatment after surgery. You cannot have received any other cancer treatments besides that immunotherapy.
Anchorage, AlaskaAges 18 years+
Hear when a new Renal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for renal cancer?
- Yes. Clin2 currently lists 252 recruiting renal cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a renal cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a renal cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.